Back to Search
Start Over
Fontolizumab Protein Design Labs.
- Source :
-
Current opinion in investigational drugs (London, England : 2000) [Curr Opin Investig Drugs] 2005 May; Vol. 6 (5), pp. 537-44. - Publication Year :
- 2005
-
Abstract
- Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for the potential treatment of autoimmune diseases. By February 2003, the company was actively seeking to outlicense the development and commercialization rights to fontolizumab outside of the US and Canada.
- Subjects :
- Animals
Antibodies, Monoclonal chemistry
Antibodies, Monoclonal, Humanized
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Drug Design
Drug Industry organization & administration
Humans
Interferon-gamma chemistry
Antibodies, Monoclonal therapeutic use
Autoimmune Diseases drug therapy
Interferon-gamma antagonists & inhibitors
Interferon-gamma therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1472-4472
- Volume :
- 6
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Current opinion in investigational drugs (London, England : 2000)
- Publication Type :
- Academic Journal
- Accession number :
- 15912969